DailyIQ
Last updatedUpdating…

DNA·Ginkgo Bioworks Holdings Inc.

$11.74
+0.21 (+1.82%)
After Hours
High
$11.80
Open
$11.07
Market Cap
0.78B
52W High
$18.22
Low
$10.40
P. Close
$11.74
P/E
-
52W Low
$5.37
Fwd P/E
-3.98
DailyIQ Est.
$6.68
Inst. Ownership
32.5%
Short Interest
11.38%
Days to Cover
2.7
Technical Score (1D)
3
BEARISH
News Sentiment
55
BULLISH
With a Technical Score of 3, Ginkgo Bioworks Holdings Inc. (DNA) sits in the bottom tier of the momentum ranking on the 1D timeframe. The bearish bias and SELL signal follow from that rank, and trend strength reads as weak. Sentiment at 55 is diverging from the chart. Because the score is relative, it can stay low even in a rising market if DNA keeps trailing its peers. $10.98 is the near-term floor and $11.90 is where a recovery attempt would meet its first test. A bottom momentum rank reflects the prior year of trading, so it changes gradually even when the stock has a strong week. For near-term direction, price levels give the earlier read: a close back above $11.90 on real volume would be the first sign of repair, while a break of $10.98 keeps the bearish trend in charge.
LOW TARGET
$5 -57.5%
4 analysts
MEAN TARGET
$8 -32.0%
6 analysts
HIGH TARGET
$11 -6.5%
2 analysts
PRICE RANGE
$5.00 - $11.00
SB / B / H / S / SS
1/1/3/5/2
DAILYIQ EST.
$6.68 (-43.2%)
Sector
Healthcare
Industry
Biotechnology
Exchange
NYQ
Country
United States
Website
Symbol
DNA
Description
Ginkgo Bioworks utilizes a cell programming platform to engineer organisms for various industries. The company's core business centers on providing research and development solutions, as well as specialized tools, to facilitate the creation and commercialization of engineered organisms and their resulting products. These offerings include functional genomics, AI models, and automation systems, catering to diverse sectors such as pharmaceuticals, agriculture, and consumer goods. Furthermore, Ginkgo Bioworks provides biosecurity services through its Canopy and Horizon platforms, which offer biomonitoring and digital surveillance capabilities to detect and analyze potential biothreats. Founded in 2008, Ginkgo Bioworks is headquartered in Boston, Massachusetts, and aims to provide innovative solutions to a wide range of industries.
Bought (1Y)
0 shares
$0
Sold (1Y)
8,792 shares
$82K
Coen Steven P.See remarks
Sell2,403 shares2026-10-05
HENRY CHRISTIAN O-
Sell5,000 shares2026-09-15
Coen Steven P.See remarks
Sell330 shares2026-08-24
Coen Steven P.See remarks
Option Exercise156 shares2026-08-21
Coen Steven P.See remarks
Option Exercise587 shares2026-08-21
8/ 100
Very bearish
Overall: Bearish
✕Revenue declining year over year
✕Negative net margin
✕Negative operating cash flow
Net Margin
-183.8%
Revenue CAGR
21.0%
Current Ratio
4.92x
Return on Equity
-61.5%
Earnings Summary
Ginkgo Bioworks (DNA) is a biotechnology company headquartered in Boston that offers a cell programming platform to engineer organisms for pharmaceuticals, agriculture, and consumer goods, along with biosecurity services through its Canopy and Horizon platforms. The firm operates in the high‑growth biotech sector, focusing on functional genomics, AI models, and automation systems that enable rapid development of engineered products. In the most recent quarters, Ginkgo reported a modest improvement in earnings per share, moving from a -$1.68 EPS in Q1 2025 to a -$1.10 EPS in Q2 2025, a 34% reduction in loss, while revenue increased from $48.3 million to $49.6 million, a 2.7% rise; however, the company still missed analyst EPS estimates in both periods, with actual losses falling short of the -$1.56667 estimate. The Q3 2025 quarter saw a reversal, with revenue falling to $38.8 million and EPS worsening to -$1.45, indicating a slowdown after the Q2 uptick. Historically, Ginkgo’s revenue has trended upward year over year, rising from $43.8 million in Q4 2024 to $49.6 million in Q2 2025, yet EPS has remained negative and has fluctuated, reflecting ongoing cash burn and investment in R&D. The company has consistently missed EPS estimates in the last four quarters, although revenue growth has been steady, suggesting that cost pressures are eroding profitability. Recent news highlights a partnership with the National Science Foundation’s X‑Labs program, granting researchers access to Ginkgo’s autonomous laboratory, and the integration of Araceli Biosciences’ Endeavor imaging instrument into its Nebula platform, both of which expand the firm’s infrastructure and data capabilities; however, analysts have downgraded the stock, citing weak fundamentals and declining revenue streams.

EPS

EstBeatMiss
$-1.95$-1.55$-1.16$-0.76$-0.36Q4'24Q1'25Q2'25Q3'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$-0.54 - -
Q1'26$-1.09$-1.28-17.3%
Q3'25$-1.24$-1.45-16.9%
Q2'25$-1.57$-1.10+29.8%
Q1'25$-1.77$-1.68+5.1%
Q4'24$-1.30$-1.21+6.7%

Revenue

EstBeatMiss
$15M$25M$35M$44M$54MQ4'24Q1'25Q2'25Q3'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$22M - -
Q1'26$42M$19M-53.6%
Q3'25 - $39M -
Q2'25 - $50M -
Q1'25 - $48M -
Q4'24 - $44M -

Market Data

DNA Stock Snapshot

BEARISH3/100
$11.76+$0.02 (0.2%)
Market cap
0.78B
Day range
$10.40 – $11.80
News sentiment
55/100 · Neutral
Analyst target
$8.00 (-32.0%)
Consensus
Sell · 12 analysts
52-week range+119.0% off low · -35.5% from high
$5.37$18.22
Price $11.76 DailyIQ Est. $6.68

Price action on DNA is defensive - rallies are being sold rather than extended. Company-specific news dominates here; sector-level flows matter less than for larger names.

Behaviour On Record

What DNA's own history says about today's numbers

Realized volatility (21d)
155.9% 99th pct
Below its peak
-98.0%
vs 200-day average
+39.0%
Up days (1y)
49%

Ginkgo Bioworks Holdings Inc. is currently running 155.9% annualised volatility over the last 21 sessions. Measured against DNA's own 5 years of daily returns rather than a market-wide average, that is the 99th percentile — an extreme by its own standards, against a typical reading of 91.5%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

DNA is trading -98.0% below its running peak. Across 4 full years on file, its median worst-drawdown-in-a-year was -74.7%, and the deepest was -91.9% in 2024. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +39.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 97th percentile — a wider gap than this stock usually carries. Over the past year DNA closed higher on 49% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 6 years of records, DNA finished the month higher 1 of 6 times, with a median return of -8.4% and an average of -4.9%. Its strongest month historically has been September at +25.6% on average, its weakest February at -23.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: DNA has opened more than 2% away from the prior close in 360 of 1,380 sessions (26.1% of the time), with the largest gaps running +15.4% and -9.0%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 1,381 daily closes between 2021-04-19 and 2026-10-15, split-adjusted, recomputed daily. Percentiles are against DNA's own 6-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of DNA's sector?

Ginkgo Bioworks Holdings Inc. sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, DNA ranks 9th of 15 tracked industries, improving.

Sector rank
#1 of 12
Sector state
Leading
Sector rotation score
100
Industry rank
#9 of 15

Options Market

What is the options market pricing for DNA?

CallsPuts

For Ginkgo Bioworks Holdings Inc.'s nearest expiry (2026-10-16, 1 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.63), with at-the-money implied volatility around 94.5%. The options market is pricing roughly a ±5.2% move by that expiry — a range of about $11.03–$12.25.

Put/call ratio (2026-10-16)
0.63
ATM implied volatility
94.5%
Total open interest
4,933
Expected move by 2026-10-16
±5.2% ($11.03–$12.25)

Analyst Rating Changes

Are analysts turning bullish or bearish on DNA?

TD Cowen most recently reiterated its rating on Ginkgo Bioworks Holdings Inc. to Hold on Oct 13, 2026 with a price target of $11 (from $9). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.

Latest action
TD Cowen — Hold
90-day upgrades
0
90-day downgrades
1
Net rating momentum
-1
DateFirmActionRatingPrice target
Oct 13, 2026TD CowenMaintainedHold$9 → $11
Sep 4, 2026BTIGReiteratedSell$5
Aug 7, 2026TD CowenDowngradeBuy → Hold$12 → $9
Mar 12, 2026BTIGMaintainedSell$9 → $5
Jan 8, 2026TD CowenMaintainedBuy$14 → $12
Aug 25, 2025BTIGMaintainedSell$6 → $9
Sep 20, 2024TD CowenMaintainedBuy$3 → $10
Aug 23, 2024BTIGMaintainedSell$0 → $7
Jul 9, 2024Goldman SachsMaintainedSell$1 → $0
Jun 26, 2024BTIGMaintainedSell$1 → $0
May 15, 2024BTIGDowngradeNeutral → Sell-
May 15, 2024Morgan StanleyMaintainedEqual-Weight$2 → $1

Peers & ETF holders

DNA peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

55/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Ginkgo Bioworks (DNA) announced that it would provide in‑kind access to its autonomous laboratory in Boston for National Science Foundation X‑Labs researchers. The company will make cloud‑lab time available, enabling remote use of robotic lab infrastructure for design, execution, and analysis of experiments. The partnership supports the NSF’s $1.5 billion X‑Labs initiative, which aims to accelerate breakthrough science. This collaboration expands Ginkgo’s reach into academic research and strengthens its position as a leader in automated biology.
What did this article say?
Ginkgo Bioworks announced it would provide in‑kind access to its autonomous laboratory for researchers in the National Science Foundation’s X‑Labs program. The company will make cloud‑lab time and protein‑testing services available to teams funded under the $1.5 billion initiative. The partnership, highlighted by the White House OSTP director, expands Ginkgo’s remote‑lab capabilities and supports breakthrough science projects. The move positions Ginkgo as a key infrastructure partner for federally funded research, potentially increasing utilization of its autonomous platforms.
What did this article say?
On October 8, Ginkgo Bioworks (DNA) announced it would provide in‑kind access to its autonomous laboratory in Boston to support the National Science Foundation’s X‑Labs program. The company will contribute cloud lab time and protein testing services to the $1.5 billion science initiative. This partnership expands DNA’s service footprint and strengthens its position in the life‑science automation market. The collaboration is expected to generate incremental revenue and enhance DNA’s reputation as a key infrastructure partner for federal research projects.
What did this article say?
Ginkgo Bioworks (DNA) and Araceli Biosciences announced a collaboration to embed Araceli’s Endeavor high‑content imaging system into Ginkgo’s Nebula autonomous laboratory in Boston. The new system can capture images of a 1,536‑well plate in under four minutes and performs real‑time analysis of each well as images are taken. No financial terms were disclosed, and the partnership does not appear to alter Ginkgo’s existing business model or financial outlook. The integration is intended to enhance laboratory throughput and data quality for Ginkgo’s synthetic biology platform.
What did this article say?
On October 8, 2026, Ginkgo Bioworks (DNA) announced the integration of Araceli Biosciences’ Endeavor high‑content imaging instrument into its autonomous Nebula lab. The Endeavor, described as the world’s fastest system, delivers real‑time cellular imaging and analysis, enabling researchers to generate large, curated datasets for training AI models in drug discovery. Nebula’s existing Reconfigurable Automation Carts (RACs) will now accommodate the new instrument, allowing modular expansion and streamlined workflow adjustments. The addition is expected to accelerate data generation and improve the quality of AI‑driven insights, though it does not represent a material shift in Ginkgo’s financial outlook.
What did this article say?
On October 7, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $11.47, reflecting a 7.57% decline from the previous session. The drop was sharper than the broader market, indicating investor concern over the company’s recent performance. The decline suggests a negative market reaction to the company’s latest earnings or guidance, though no specific catalyst was detailed in the brief. The move may impact short-term investor sentiment and trading volume. Overall, the price movement signals a modest negative outlook for the near term.
What did this article say?
Ginkgo Bioworks Holdings (DNA) received a sell rating from an analyst citing weak fundamentals and a valuation that has outpaced the company’s business. The report highlighted declining revenue streams and increasing cash burn as key concerns. The analyst noted that the company’s AI/biotech hype has not translated into sustainable growth, reinforcing the negative outlook. This assessment signals a material downgrade for investors wary of the company’s financial trajectory.
What did this article say?
On October 1, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.50, down 2.57% from the previous day, trailing broader market gains. The decline followed a forecast of a negative earnings per share of $0.58 and a revenue projection of $20.5 million, a 47% drop from the prior year’s quarter. Analysts noted that the company’s full‑year guidance also reflected a decline in revenue and earnings, adding to investor concern. The stock’s performance was muted relative to the S&P 500’s modest gain and the Nasdaq’s slight rise, underscoring a cautious market stance toward the biotech firm.
What did this article say?
Ginkgo Bioworks (DNA) experienced a notable share price rally after announcing a partnership with a major pharmaceutical company. The partnership generated optimism and drove the stock higher during the week. However, the company’s Q2 results revealed a significant revenue decline, increasing losses and cash burn. The positive market reaction was tempered by the negative financial outlook, leaving investors with a mixed view of the company’s prospects.
What did this article say?
Ginkgo Bioworks (DNA) fell 8.4% in the latest session, outpacing the broader market and tech indices. The company is expected to report a negative earnings per share of $0.58, a decline from prior periods, while revenue is projected to drop 47% year‑over‑year. Analysts note a 60% year‑over‑year earnings growth, but the negative guidance signals a potential earnings miss. The market reaction reflects concerns over the company’s profitability trajectory and upcoming quarterly results.

Technical Analysis

Real-time indicators across multiple timeframes

3
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $201.30M combined position · 16 adding, 6 trimming, 3 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▲ Buy4,282,9036.66%$42.44M2026-08-07
Viking Global Investors LP• Hold3,577,1285.57%$35.45M2026-08-14
Vanguard Group Inc▲ Buy2,900,9524.51%$24.11M2026-01-29
Baillie Gifford & Co• Hold2,391,6493.72%$23.70M2026-08-06
Anchorage Capital Group, L.L.C.• Hold1,746,3632.72%$17.31M2026-08-14
Geode Capital Management, LLC▲ Buy1,222,0161.90%$12.11M2026-08-12
Millennium Management LLC▲ Buy638,6760.99%$6.33M2026-08-14
AQR Capital Management LLC▲ Buy621,6250.97%$6.16M2026-08-14
Goldman Sachs Group Inc▼ Sell607,3760.94%$6.02M2026-08-14
Bank of America Corp▲ Buy545,8520.85%$5.41M2026-08-14
Renaissance Technologies LLC▲ Buy539,8560.84%$5.35M2026-08-13
Northern Trust Corp▲ Buy405,1410.63%$4.01M2026-08-13
Invesco Ltd.▼ Sell211,7230.33%$2.10M2026-08-14
Caxton Associates LLP▲ Buy154,6470.24%$1.53M2026-08-14
D. E. Shaw & Co., Inc.▲ Buy151,3560.24%$1.50M2026-08-14
Morgan Stanley▼ Sell144,3140.22%$1.43M2026-08-13
JPMorgan Chase & Co▲ Buy134,0400.21%$1.37M2026-08-12
Citadel Advisors LLC▲ Buy130,9350.20%$1.30M2026-09-02
Marshall Wace, LLP▼ Sell77,9370.12%$772.4K2026-08-13
Allstate Corp▲ Buy70,4550.11%$698.2K2026-08-13
Two Sigma Investments, LP▼ Sell60,4540.09%$599.1K2026-08-14
Citigroup Inc▲ Buy45,8260.07%$454.1K2026-08-03
Wells Fargo & Company▲ Buy41,9080.07%$415.3K2026-08-14
Susquehanna International Group, LLP▼ Sell39,3720.06%$390.2K2026-08-14
AllianceBernstein L.P.▲ Buy55,7920.09%$342.0K2026-08-14
Q2 2026 flow:2.48M sh bought ($24.45M)867.1K sh sold ($8.59M)net +1.61M sh (+$15.86M)